INT120515

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.66
First Reported 1999
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 13
Total Number 13
Disease Relevance 4.33
Pain Relevance 2.60

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Otc) cytoplasm (Otc)
Anatomy Link Frequency
canal 1
Otc (Rattus norvegicus)
Pain Link Frequency Relevance Heat
cINOD 27 99.84 Very High Very High Very High
Arthritis 13 98.08 Very High Very High Very High
complementary and alternative medicine 1 97.40 Very High Very High Very High
aspirin 97 97.28 Very High Very High Very High
Pain 21 94.84 High High
Migraine 1 89.40 High High
headache 1 88.84 High High
Inflammation 8 85.04 High High
colic 3 79.12 Quite High
drug abuse 1 72.76 Quite High
Disease Link Frequency Relevance Heat
Ornithine Transcarbamylase Deficiency 2 100.00 Very High Very High Very High
Toxicity 2 99.80 Very High Very High Very High
Arthritis 13 98.08 Very High Very High Very High
Disease 9 97.66 Very High Very High Very High
Infection 15 96.64 Very High Very High Very High
Pain 17 94.84 High High
Headache 2 89.40 High High
Chronic Disease 7 87.76 High High
Hypersensitivity 6 86.80 High High
INFLAMMATION 11 85.04 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Nitric oxide synthesis in ornithine transcarbamylase deficiency: possible involvement of low no synthesis in clinical manifestations of urea cycle defect.
Gene_expression (synthesis) of ornithine transcarbamylase associated with ornithine transcarbamylase deficiency
1) Confidence 0.66 Published 2004 Journal J. Pediatr. Section Title Doc Link 15289781 Disease Relevance 0.37 Pain Relevance 0.18
METHODS: OTC products were administered orally to rats in standard assays for suppressing experimental arthritis and fever and for determining potential gastrotoxicity.
Gene_expression (products) of OTC
2) Confidence 0.59 Published 1999 Journal Inflammopharmacology Section Body Doc Link 18597151 Disease Relevance 0.10 Pain Relevance 0
Other authors have recently reached the same conclusion for OTC
Gene_expression (conclusion) of OTC
3) Confidence 0.58 Published 2001 Journal BMC Clin Pharmacol Section Body Doc Link PMC32172 Disease Relevance 0.10 Pain Relevance 0.41
The treatment options include OTC products, such as fluoride and/or potassium enriched mouth washes and dentifrices, or in-office treatments, such as high content fluoride varnishes and gels, potassium oxalate chelating agents, Glutaraldehyde containing tissue fixating agents, bonding materials, low viscosity glass ionomers and even non-conservative treatments such as root canal therapy or mucogingival surgical interventions.
Gene_expression (products) of OTC in canal
4) Confidence 0.58 Published 2010 Journal Refuat Hapeh Vehashinayim Section Abstract Doc Link 20597258 Disease Relevance 0.57 Pain Relevance 0.33
CONCLUSION: Anecdotal evidence suggests that a component in OTC products labeled as kudzu may prove useful in managing cluster headache.
Gene_expression (products) of OTC
5) Confidence 0.58 Published 2009 Journal Headache Section Body Doc Link 19125878 Disease Relevance 0.07 Pain Relevance 0
Treatment strategies include (1) inquiring about prescription, OTC, and herbal drug use at the initial examination (even though many individuals are drug-abuse savvy, some are naive and do not realize that OTC medications can be problematic); (2) inquiring about drug use during office visits; (3) providing disposal containers that patients can use to dispose of their unused or unneeded prescription or OTC medications; (4) treating pain aggressively and appropriately; (5) practicing careful record keeping of prescription refills and controls over prescription blanks; (6) referring patients who are addicted to medications to 12-step programs such as Alcoholic Anonymous, Narcotics Anonymous, and Pills Anonymous; and (7) considering detoxification.
Gene_expression (prescription) of OTC associated with pain
6) Confidence 0.58 Published 2008 Journal Journal of the American Board of Family Medicine : JABFM Section Abstract Doc Link 18178702 Disease Relevance 0.34 Pain Relevance 0.30
The F/M ratio for the Rx medication group is generally higher than for the OTC group for most categories.
Gene_expression (group) of OTC
7) Confidence 0.52 Published 2004 Journal BMC Womens Health Section Body Doc Link PMC2096677 Disease Relevance 0.39 Pain Relevance 0.22
Several OTC products not licensed for use in this age group were reported.
Gene_expression (products) of OTC
8) Confidence 0.41 Published 2007 Journal Eur J Clin Pharmacol Section Body Doc Link PMC1779627 Disease Relevance 0.23 Pain Relevance 0.15
 ; (c) reliability of composition, and reproducibility (especially of natural products); (d) general safety; (e) interactions with other medications; (f) honest labelling (in the absence of stricter guidelines).A particularly difficult problem is to know how to recognise a 'drug of choice', particularly for such a multi-faceted disease as chronic arthritis, when there is so little information about the actual pharmacology/potential toxicity of these OTC products in the standard drug compendia and other readily available reference texts.This grey area can only be illuminated by (i) further introduction (and enforcement) of adequate standards/quality controls for products offered OTC; (ii) earliest prosecution of clinical trials to supercede unverified testimonial claims; (iii) appropriate funding to research/establish basic pharmacology of the active principles.In summary, more research, more regulation, and more realistic investment will be required to dispel present uncertainty about which non-NSAID drugs/nutriceuticals are indeed effective against arthritis/other forms of inflammation, and which are not.
Gene_expression (products) of OTC associated with toxicity, inflammation, cinod, disease and arthritis
9) Confidence 0.36 Published 1999 Journal Inflammopharmacology Section Abstract Doc Link 17638094 Disease Relevance 0.74 Pain Relevance 0.46
 ; (c) reliability of composition, and reproducibility (especially of natural products); (d) general safety; (e) interactions with other medications; (f) honest labelling (in the absence of stricter guidelines).A particularly difficult problem is to know how to recognise a 'drug of choice', particularly for such a multi-faceted disease as chronic arthritis, when there is so little information about the actual pharmacology/potential toxicity of these OTC products in the standard drug compendia and other readily available reference texts.This grey area can only be illuminated by (i) further introduction (and enforcement) of adequate standards/quality controls for products offered OTC; (ii) earliest prosecution of clinical trials to supercede unverified testimonial claims; (iii) appropriate funding to research/establish basic pharmacology of the active principles.In summary, more research, more regulation, and more realistic investment will be required to dispel present uncertainty about which non-NSAID drugs/nutriceuticals are indeed effective against arthritis/other forms of inflammation, and which are not.
Gene_expression (prosecution) of OTC associated with toxicity, inflammation, cinod, disease and arthritis
10) Confidence 0.36 Published 1999 Journal Inflammopharmacology Section Abstract Doc Link 17638094 Disease Relevance 0.71 Pain Relevance 0.46
However, our search did not uncover any OTC products utilizing these ingredients that bore a label claiming to “cure most vaginal yeast infections
Gene_expression (products) of OTC associated with infection
11) Confidence 0.30 Published 2007 Journal Infectious Diseases in Obstetrics and Gynecology Section Body Doc Link PMC1986759 Disease Relevance 0.66 Pain Relevance 0.07
First, it is not in the FDA's regulatory purview to assure that OTC drug products are as clinically effective as possible, only that they are clinically effective and safe.
Gene_expression (products) of OTC
12) Confidence 0.29 Published 2006 Journal BMC Oral Health Section Body Doc Link PMC2147065 Disease Relevance 0 Pain Relevance 0.03
A total of 2664 beneficiaries were dispensed prescriptions and OTC products that, if taken as directed, would have resulted in more than 100 days of acetaminophen doses of 4 g/day or more during the study year.
Gene_expression (products) of OTC
13) Confidence 0.18 Published 2010 Journal Ann Pharmacother Section Body Doc Link 20551297 Disease Relevance 0.06 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox